Duvyzat (Givinostat) is an innovative drug used to treat Duchenne muscular dystrophy (DMD). It is important for patients and their families to understand its price, treatment effects, and dietary precautions. This article will explore these aspects in detail to help readers better understand Duvyzat.
How much is a box of Duvyzat?
The original research company of Duvyzat is ITF Therapeutics, a subsidiary of Italfarmaco Group. Duvyzat was approved on March 21, 2024 and subsequently launched in the United States.
Spanish Italfarmaco S.p.A version of Duvyzat
Duvyzat is currently produced by Spanish Italfarmaco S.p.A. in a box of 140ml. The specific cost depends on the patient's weight and required dosage.
Considering the high price and complicated procurement process, it is recommended that patients or their families cooperate with professional pharmaceutical consulting companies to obtain the required drugs more smoothly and ensure the continuity of the treatment process. The above prices are for reference only.
The therapeutic effect of Duvyzat
Innovative therapies have brought new hope to DMD patients, especially those who do not respond well to traditional treatments.
Indications and mechanisms of action
Duvyzat is mainly used to treat Duchenne muscular dystrophy (DMD) and is suitable for patients aged 6 years and above. It exerts its therapeutic effect by inhibiting histone deacetylase (HDAC) and regulating the activity of HDAC. This innovative therapy is the eighth DMD therapy approved for marketing in the United States and the first non-steroidal drug approved for the treatment of all genetic variant DMD patients.
Clinical trial results
In clinical trials, Duvyzat showed significant efficacy. For example, some patients' muscle function improved and their quality of life improved. However, like other drugs, Duvyzat may also cause some side effects, such as thrombocytopenia, anemia, diarrhea, etc.
Understanding these clinical data helps to evaluate the effectiveness and potential risks of treatment, so as to make more scientific and reasonable treatment decisions.
Dietary considerations for patients taking Duvyzat
Adjusting the dietary structure to match the use of the drug can optimize the treatment effect while reducing unnecessary side effects.
High-fat meal and drug absorption
Studies have shown that taking Duvyzat with a high-fat meal can increase the drug exposure (AUC) of Duvyzat by about 40%, the peak concentration (Cmax) by about 23%, and Tmax by about 23%. This means that a reasonable diet, especially choosing foods containing an appropriate amount of fat, may help improve the efficacy of the drug.
Management of abnormal lipid metabolism
The use of Duvyzat may lead to an increase in serum triglycerides, and the test values of some patients exceed 300 mg/dL. Therefore, special attention should be paid to lipid metabolism during treatment, and dietary intervention measures should be taken when necessary, such as reducing the intake of saturated fatty acids and increasing the proportion of dietary fiber.
A reasonable dietary structure not only helps to control abnormal lipid metabolism, but also improves overall health and supports the optimal efficacy of Duvyzat.
